The ELEVATE (NCT05563220) trial is a phase Ib/II umbrella study, where the clinical performance of elacestrant joined with either alpelisib, capivasertib, everolimus, palbociclib, abemaciclib, or ribociclib is assessed in ER+/HER2− advanced/relapsed breast cancer [123]. Here, ERBB2 is linked to breast carcinoma.